Skip to main content
. 2024 Oct 2;10(40):eado8231. doi: 10.1126/sciadv.ado8231

Fig. 2. Associations and correlations of SRSF6 expression levels with clinical parameters of PCa aggressiveness.

Fig. 2.

(A and B) Correlation of Gleason score with SRSF6 mRNA levels in the prostatectomy (A) and biopsy (B) cohorts. (C to E) Associations of SRSF6 mRNA levels and T stage (C), lymphovascular invasion (D), and perineural infiltration (E) in the prostatectomy cohort. (F and G) Associations of SRSF6 mRNA levels and perineural infiltration (F) and metastasis (LV, low volume; HV, high volume) (G) in the biopsy cohort. (H and I) Association between biochemical progression-free survival and SRSF6 mRNA levels [quartile 1 (Q1) versus Q2-4)] in the prostatectomy (H) and TCGA (I) cohorts. SRSF6 mRNA levels are adjusted by normalization factor (calculated from ACTB and GAPDH expression levels). Correlations data are represented by mean (connecting line) and error bands (pointed line). Data of associations represent the means ± SEM of mRNA expression levels. Asterisks (*P < 0.05, **P < 0.01, and ***P < 0.001) indicate statistically significant differences between groups. LR, log-rank.